These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 20192279)

  • 1. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M; Prica C
    Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
    Pandi-Perumal SR; Trakht I; Srinivasan V; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
    World J Biol Psychiatry; 2009; 10(4 Pt 2):342-54. PubMed ID: 18609422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine: a novel pharmacological approach to treating depression.
    Owen RT
    Drugs Today (Barc); 2009 Aug; 45(8):599-608. PubMed ID: 19927226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
    Pardini M; Cordano C; Benassi F; Mattei C; Sassos D; Guida S; Serrati C; Primavera A; Amore M; Cocito L; Emberti Gialloreti L
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):939-44. PubMed ID: 24636462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.